

**Dr. Mark A. Tepper**  
**[Mtepper79@gmail.com](mailto:Mtepper79@gmail.com)**  
**Phone 617-413-3020**



Dr. Tepper has over 25 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & development programs that span a wide array of therapeutic areas including Oncology, Immunology, Endocrinology, Metabolic Diseases, Inflammation and Pain, and novel technology development programs in the areas of RNA interference, biosensors, microfluidics, and biomaterials. Dr Tepper is currently Founder, President and Chief Scientific Officer of Corbus Pharmaceuticals (NASDAQ: CRBP). During the last 15 years, Dr. Tepper has founded and served as founding management of 4 biotech companies based on technology spun out from academic institutions. His role in these companies included technology sourcing, due diligence, company formation and capitalization, business and commercial plan, IP licenses, management recruitment, and serving as a member of the C-suite and board of directors. Dr. Tepper has raised over \$300M in capital and brought two companies public. His most recent venture Corbus Pharmaceuticals (NASDAQ: CRBP) is developing breakthrough medicine based on the endocannabinoid system which promote the resolution of inflammation for the treatment of serious life-threatening inflammatory and fibrotic diseases. The lead product is currently in phase III trials in systemic sclerosis and dermatomyositis, and in phase II clinical trials in cystic fibrosis and lupus. In 2014, Corbus IPO'ed on the NASDAQ, and currently has a market cap of ~\$400M Other companies ha founded include; Primatope Therapeutics (acquired by NASDAQ: Kiniksa), developing best-in-class humanized

CD40 antagonist monoclonal antibodies to treat autoimmune diseases and organ transplant rejection; NKT Therapeutics, developing medicines based on Natural Killer T Cells to treat sickle cell crisis, asthma and autoimmune diseases; Rxi Pharmaceuticals (NASDAQ:RXII) developing RNAi therapeutics to treat wound healing and scarring; and Arradial (acquired by Bioprocessors Inc), which developed a microfluidics based screening platform for identifying new drugs targeting novel human genome targets.

Dr. Tepper earned a Ph.D. in Biochemistry & Biophysics from Columbia University, College of Physicians and Surgeons, New York, and a B.A in Chemistry with Highest Honors from Clark University, Worcester, Mass. He did his postdoctoral fellowship at University of Massachusetts Medical School, Worcester in the laboratory of Michael P. Czech. He has over 60 published scientific papers and is the co-inventor of multiple patents.